Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 4:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 4
2 (100.0%)An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
Phase 4
Not yet recruiting
- Conditions
- Schizophrenia
- Interventions
- Drug: Xanomeline/Trospium
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Vanguard Research Group
- Target Recruit Count
- 172
- Registration Number
- NCT06923891
- Locations
- 🇺🇸
Clinical Site, Richmond, Texas, United States
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
Phase 4
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Any FDA approved antipsychotic agent
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Vanguard Research Group
- Target Recruit Count
- 489
- Registration Number
- NCT02360319
- Locations
- 🇺🇸
La Frontera, Tucson, Arizona, United States
🇺🇸San Fernando Mental Health Center, Granada Hills, California, United States
🇺🇸Stanford School of Medicine, Palo Alto, California, United States
News
No news found